查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1590855

痛风药物市场：按药物类别、治疗方法、给药途径、应用划分 - 全球预测 2025-2030

Gout Therapeutics Market by Drug Class (Colchicine, Corticosteroids, NSAIDs), Treatment (Uricosuria Medication, Xanthine Oxidase Inhibitor), Route of Administration, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年痛风药物市场价值为27.5亿美元，预计到2024年将达到30.5亿美元，复合年增长率为10.95%，预计到2030年将达到57亿美元。

痛风药物的范围和定义包括用于控制和缓解痛风相关症状的药物和治疗方法，痛风是一种发炎关节炎，其特征是关节突然疼痛、肿胀和发红。由于生活方式因素和人口老化，这种疾病的盛行率不断增加，因此需要痛风药物。这些治疗药物适用于急性痛风发作、慢性治疗和復发预防，同时最大限度地降低合併症的风险。最终用途主要包括医院、诊所和专门的风湿病中心，在那里实施客製化的治疗方法。市场成长受到痛风盛行率上升、生物製药进步以及医疗保健提供者和患者对早期诊断和治疗选择的认识不断提高等因素的影响。新型治疗药物（包括降尿酸疗法和生物製药）的推出带来了潜在的市场机会。抓住这些机会的建议包括投资创新治疗方法的研发以及建立策略伙伴关係以加强全球分销网络。然而，市场成长面临着治疗成本高、潜在副作用和严格的监管要求等限制，阻碍了市场的快速核准和广泛采用。此外，新兴市场患者对长期治疗方法依从性的挑战以及认知度较低，使市场动态更加复杂。儘管存在这些挑战，个人化医疗、生物相似药开发以及在治疗优化中使用人工智慧进行预测分析等创新领域正在为研究和业务成长铺平道路。市场竞争仍然激烈，主要企业专注于透过收购和联盟扩大其产品组合，需要不断创新和适应才能占领重要的市场占有率。寻求发展的公司应专注于以患者为中心的全面方法，利用数位健康技术，并解决痛风和合併症的整体管理问题。

主要市场统计
基准年[2023] 27.5亿美元
预测年份 [2024] 30.5亿美元
预测年份 [2030] 57亿美元
复合年增长率（%） 10.95%

市场动态：快速发展的痛风治疗市场的关键市场洞察

供需的动态交互作用正在改变痛风药物市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 痛风盛行率上升与饮酒消费量增加有关
    • 老年人口增加
    • 降尿酸剂细分领域介绍
  • 市场限制因素
    • 学名药竞争和药品价格上涨
  • 市场机会
    • 透过诊断影像技术的进步加深对痛风的了解
    • 再生医学相关研究开发的活性化
  • 市场挑战
    • 痛风药物的副作用

波特五力：驾驭痛风药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解痛风药物市场的外部影响

外部宏观环境因素在塑造痛风治疗药物市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解痛风治疗药物市场的竞争状况

对痛风治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵痛风药物市场供应商的绩效评估

FPNV定位矩阵是评估痛风治疗药物市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议描绘痛风治疗药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对痛风治疗药物市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 痛风发病率增加与饮酒消费量增加有关
      • 人口老化加剧
      • 降尿酸剂细分领域介绍
    • 抑制因素
      • 学名药竞争及高成本
    • 机会
      • 诊断影像技术的进步加深了我们对痛风的认识
      • 扩大再生医学的研发活动
    • 任务
      • 痛风药物的副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章痛风药物市场：依药物类别

  • 秋水仙碱
  • 皮质类固醇
  • NSAIDs
  • 降低尿酸水平的药物

第七章痛风药物市场：依治疗方法

  • 尿酸尿症治疗药
  • 黄嘌呤氧化酶抑制剂

第八章痛风药物市场：依给药途径

  • 口服
  • 胃肠外的

第九章痛风治疗药物市场：依应用分类

  • 急性痛风
  • 慢性痛风

第十章 北美和南美痛风药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区痛风药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的痛风治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bristol Myers Squibb Company
  • CH Boehringer Sohn AG & Co. KG
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Horizon Pharma PLC
  • Lannett Company, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teijin Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-4349B3591E87

The Gout Therapeutics Market was valued at USD 2.75 billion in 2023, expected to reach USD 3.05 billion in 2024, and is projected to grow at a CAGR of 10.95%, to USD 5.70 billion by 2030.

The scope and definition of gout therapeutics encompass medications and treatments developed to manage and alleviate symptoms associated with gout, a form of inflammatory arthritis characterized by sudden pain, swelling, and redness in the joints. The necessity of gout therapeutics arises from the increasing prevalence of the condition, driven by lifestyle factors and ageing populations. These therapeutics find application in acute gout attacks, chronic management, and prevention of recurrence while minimizing the risk of comorbidities. End-use scope mainly involves hospitals, clinics, and specialized rheumatology centers where tailored treatment regimens are administered. Market growth is influenced by factors such as the rising incidence of gout, advancements in biologics, and increasing awareness amongst healthcare providers and patients regarding early diagnosis and treatment options. The introduction of novel therapies, including urate-lowering therapies and biologics, presents potential market opportunities. Recommendations to seize these opportunities include investing in R&D for innovative therapies and engaging in strategic partnerships to enhance distribution networks globally. However, market growth faces limitations such as high treatment costs, potential side effects, and stringent regulatory requirements that hinder quick market approvals and wider adoption. Additionally, challenges in patient adherence to long-term treatment regimens and limited awareness in emerging markets further complicate market dynamics. Despite these challenges, areas of innovation such as personalized medicine, development of biosimilars, and the use of AI for predictive analytics in treatment optimization open avenues for research and business growth. The nature of the market remains competitive, with key players focusing on expanding their portfolios through acquisitions and collaborations, necessitating constant innovation and adaptation to capture significant market share. Companies striving for growth should focus on comprehensive patient-centric approaches, leveraging digital health technologies and addressing the holistic management of comorbid conditions along with gout.

KEY MARKET STATISTICS
Base Year [2023] USD 2.75 billion
Estimated Year [2024] USD 3.05 billion
Forecast Year [2030] USD 5.70 billion
CAGR (%) 10.95%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gout Therapeutics Market

The Gout Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of Gout with increasing alcohol consumption
    • Growing geriatric population
    • Introduction to urate-lowering agents segment
  • Market Restraints
    • Competition from generic drugs and high cost of drugs
  • Market Opportunities
    • Technological advancements in imaging modalities improved understanding of gout
    • Increasing R&D activities on regenerative medicines
  • Market Challenges
    • Side Effects of Gout Therapeutic Drugs

Porter's Five Forces: A Strategic Tool for Navigating the Gout Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gout Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gout Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gout Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gout Therapeutics Market

A detailed market share analysis in the Gout Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gout Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gout Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Gout Therapeutics Market

A strategic analysis of the Gout Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gout Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., AstraZeneca PLC, Bristol Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Horizon Pharma PLC, Lannett Company, Inc., Merck & Co., Inc., Novartis AG, Regeneron Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Teijin Limited, Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Gout Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Colchicine, Corticosteroids, NSAIDs, and Urate-Lowering Agents.
  • Based on Treatment, market is studied across Uricosuria Medication and Xanthine Oxidase Inhibitor.
  • Based on Route of Administration, market is studied across Oral and Parenteral.
  • Based on Application, market is studied across Acute Gout and Chronic Gout.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of Gout with increasing alcohol consumption
      • 5.1.1.2. Growing geriatric population
      • 5.1.1.3. Introduction to urate-lowering agents segment
    • 5.1.2. Restraints
      • 5.1.2.1. Competition from generic drugs and high cost of drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in imaging modalities improved understanding of gout
      • 5.1.3.2. Increasing R&D activities on regenerative medicines
    • 5.1.4. Challenges
      • 5.1.4.1. Side Effects of Gout Therapeutic Drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Gout Therapeutics Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Colchicine
  • 6.3. Corticosteroids
  • 6.4. NSAIDs
  • 6.5. Urate-Lowering Agents

7. Gout Therapeutics Market, by Treatment

  • 7.1. Introduction
  • 7.2. Uricosuria Medication
  • 7.3. Xanthine Oxidase Inhibitor

8. Gout Therapeutics Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral

9. Gout Therapeutics Market, by Application

  • 9.1. Introduction
  • 9.2. Acute Gout
  • 9.3. Chronic Gout

10. Americas Gout Therapeutics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Gout Therapeutics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Gout Therapeutics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Astellas Pharma Inc.
  • 2. AstraZeneca PLC
  • 3. Bristol Myers Squibb Company
  • 4. C.H. Boehringer Sohn AG & Co. KG
  • 5. GlaxoSmithKline PLC
  • 6. Hikma Pharmaceuticals PLC
  • 7. Horizon Pharma PLC
  • 8. Lannett Company, Inc.
  • 9. Merck & Co., Inc.
  • 10. Novartis AG
  • 11. Regeneron Pharmaceuticals, Inc.
  • 12. Takeda Pharmaceutical Company Limited
  • 13. Teijin Limited
  • 14. Teva Pharmaceutical Industries Ltd.
  • 15. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GOUT THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. GOUT THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GOUT THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. GOUT THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. GOUT THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GOUT THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GOUT THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GOUT THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COLCHICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URATE-LOWERING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIA MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ACUTE GOUT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY CHRONIC GOUT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. GOUT THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. GOUT THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023